Evidence map›Paper›PMID 39540380›Full record

ReviewRevista de neurologia2024

[Glioblastoma and its interaction with neurogenesis].

B Rodríguez-Mendoza, A Figueroa-González, G Cano-Herrera, L E Gutierrez-Rosas, C I Romero-Torres, L O Victoria-Garcia, P Gonzalez-Castillo, H Guerrero-Cázares, A Ibarra

Abstract readEnglish AbstractReview
In one paragraph

Review in Revista de neurologia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

B Rodríguez-MendozaUniversidad Anáhuac México Norte, México DF, México.
A Figueroa-GonzálezMayo Clinic, Jacksonville, EE.UU.
G Cano-HerreraUniversidad Anáhuac México Norte, México DF, México.
L E Gutierrez-RosasUniversidad Anáhuac México Norte, México DF, México.
C I Romero-TorresUniversidad Anáhuac México Norte, México DF, México.
L O Victoria-GarciaUniversidad Anáhuac México Norte, México DF, México.
P Gonzalez-CastilloUniversidad Anáhuac México Norte, México DF, México.
H Guerrero-CázaresMayo Clinic, Jacksonville, EE.UU.
A IbarraUniversidad Anáhuac México Norte, México DF, México.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is the most frequent and aggressive malignant primary tumor of the central nervous system in adults, with an incidence of 3.23 per 100,000 people. Despite the existence of various therapeutic approaches, the absence of a cure and the unfavorable prognosis persist for this neoplasm, with a median survival of approximately 8-15 months and a 5-year survival rate of 6.9%. In this review, we address the epidemiology, histopathology, molecular characteristics, and treatment of GBM. We highlight the relationship of GBM with the microenvironment in the lateral ventricle wall and the cerebrospinal fluid. The location of GBM in this region results in more aggressive tumors and shorter life expectancy for patients. Understanding the malignancy mechanisms that hinder remission, treatment, and positive prognosis opens the possibility of improving diagnostic and therapeutic interventions against GBM.

Indexed as

Brain NeoplasmsGlioblastomaNeurogenesisHumansLateral VentriclesTumor Microenvironment

Identifiers

PMID39540380
PMCPMC11605900

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.